You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. CBTpro: Scaling up CBT for psychosis using simulated patients and spoken language technologies

    SBC: LYSSN.IO, INC            Topic: 104

    Psychosis resulting from schizophrenia spectrum disorders and major mood disorders is one of the most disabling health concerns worldwide. Evidence-based psychotherapeutic interventions are recommended as standard of care by national psychosis treatment guidelines but are rarely accessible. Cognitive Behavioral Therapy for psychosis (CBTp) is the most well-researched psychotherapy for psychotic di ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Development of gene therapy product for treating MPS IIIB

    SBC: NEUROGT INC            Topic: 105

    Project Summary NeuroGT, Inc is a new start-up company founded by Dr. Haiyan Fu, Associate professor in the Gene Therapy Center at University of North Carolina at Chapel Hill, with the mission of develop and commercialize effective gene therapy products to treat rare neurogenetic diseases in humans. The goal of this project is to develop an effective gene therapy product targeting the root cause f ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Nitric Oxide Microfluidic Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Point-of-care antigen detection assay for early diagnosis of Ebola virus disease (EVD)

    SBC: Inbios International Inc            Topic: NIAID

    Project Summary Ebolavirus spp. cause a severe hemorrhagic fever known as Ebola virus disease (EVD). EVD is a serious public health concern, both as an emerging infectious disease and a potential biothreat. The 2013-2016 Ebola pandemic in West Africa brought global attention to the challenges associated with controlling an Ebola. The ongoing outbreak in the Democratic Republic of Congo, which rece ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. New Inhibitors of HIV latency reactivation

    SBC: Ithax Pharmaceuticals Inc            Topic: NIAID

    ABSTRACTCompany - Ithax Pharmaceutical is a new spin-off biotechnology company, located in Seattle, focused on developing proprietary small molecule chemistry to target RNA. The experience of its founders spans virology, drug design and RNA structure and function, and gives it a unique technological expertise in the RNA-targeting space. Their commercial expertise includes the successful founding, ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Single Agent Antibiofilm Antibiotics

    SBC: Synoxa Sciences, Inc            Topic: NIAID

    Project Summary Natural products have served as a productive source of drugs over the past decades and have represented, or been the inspiration for, a majority of antimicrobial compounds that have entered the clinic. The goal of this proposal is to develop novel antibacterial agents based on the marine natural product lipoxazolidinone A to treat recalcitrant Gram-positive infections. These scaffo ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Natural Product Inspired Adjuvants to Treat Tolerant Infections

    SBC: Synoxa Sciences, Inc            Topic: NIAID

    Project Summary Natural products have served as a productive source of drugs over the past decades and have represented, or been the inspiration for, a majority of antimicrobial compounds that have entered the clinic. The goal of this proposal is to develop novel antibacterial adjuvants based on the marine natural product synoxazolidinone B to treat Gram-positive orthopedic joint infections. These ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Examination of a novel potential therapy for autonomic dysreflexia

    SBC: Dignify Therapeutics LLC            Topic: NINDS

    PROJECT SUMMARY/ABSTRACT Autonomic dysreflexia (AD) is a potentially life-threatening hypertensive crisis that predominantly affects individuals with a spinal cord injury (SCI) above T6. AD can be triggered idiopathically or by distention or manipulation of pelvic visceral organs, especially the bladder and bowel, which can occur with catheterization and fecal evacuation procedures that are necess ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Development of wearable technology to enable therapy personalization of 177Lu DOTATATE for neuroendocrine tumors

    SBC: PRECISION SENSING LLC            Topic: 102

    For patients with metastatic, somatostatin-receptor-2 (SSTR2) positive neuroendocrine tumors (NETs), targeted therapy using 177Lu-DOTATATE greatly increases progression-free survival (PFS), as shown in the NETTER-1 trial. PFS at month 20 was 65.2% (95% CI, 50.0 - 76.8) for midgut NETs treated with 177Lu- DOTATATE alone compared to 10.8% (95% CI, 3.5 - 23.0) in a control group receiving 60 mg octre ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Using Mobile Devices for Neurofeedback to Reduce Opioid Use in Chronic Pain

    SBC: CrossComm, Inc.            Topic: NIDA

    Abstract One in five Americans has chronic pain. Many pharmacological pain interventions exist but increase risk of opioid use disorder (OUD). As a result, there is an urgent need for non-addictive pain treatments. One non- addictive pain treatments is neurofeedback, or electroencephalogram (EEG) biofeedback, which trains patients to regulate brain states linked to physiological relaxation. Neurof ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government